Animal anti-HBV responses read against the human seroprotection threshold (>=10 mIU/ml); response depended on CpG adjuvant dose
“The immunogenicity studies also demonstrated that the anti-HBV antibody response and more importantly the frequency of animals responding with antibody levels ≥10 mIU/ml (the defined threshold for seroprotection in humans) is depending on the 1018 ISS dose.”
CpG adjuvant judged potent: far higher anti-HBV responses than HBsAg alone or alum-adjuvanted comparator
“The anti-HBV antibody response after two administrations of the vaccine candidate was much higher in magnitude in comparison to injections with an equal dose of HBsAg alone or a licensed comparator (HBsAg antigen plus aluminium). This indicates that the 1018 ISS is a potent adjuvant.”